Fractyl Health
Lexington
About Fractyl Health
Fractyl Health develops innovative medical device solutions for the treatment of chronic diseases. The growing product pipeline leverages our minimally invasive procedural therapy, Revita DMR (duodenal mucosal resurfacing), which is designed to rejuvenate the lining of the duodenum and improve patient health. They envision a world with better solutions to chronic diseases through the use of less invasive, device-based therapies that will lessen the burden on patients, physicians, and payers. Fractyl Health aims to bring curative therapies to the large populations of patients with metabolic disease.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 101 – 250
- Estimated revenue: Less than $1M
- Total funding: $338.2M
- Funding stage: IPO
- Last round: Post-IPO Equity (Sep 2025)
- Ticker: nasdaq:GUTS
- Website: fractyl.com
- Phone: +117819028800
Industries & Categories
Biotechnology, Health Care, Medical Device, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/fractyl-health-29413 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.